Methicillin-resistant Staphylococcus aureus bacteremia with elevated vancomycin minimum inhibitory concentrations
- PMID: 37179762
- PMCID: PMC10173282
- DOI: 10.1017/ash.2023.163
Methicillin-resistant Staphylococcus aureus bacteremia with elevated vancomycin minimum inhibitory concentrations
Abstract
This case-control study of 25 cases with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia with vancomycin minimum inhibitory concentration (MIC) ≥ 2 µg/mL and 391 controls (MIC < 2 µg/mL) characterized the clinical characteristics, treatments, and outcomes associated with elevated vancomycin MIC. Elevated vancomycin MIC was associated with baseline hemodialysis, prior MRSA colonization, and metastatic infection.
© The Author(s) 2023.
Conflict of interest statement
Dr. Altman has received institutional funding from participation in ContraFect corporation clinical trials. The other authors have no financial or other conflicts of interest to disclose.
References
-
- Liu C, Bayer A, Cosgrove SE, Daum RS. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus Infections in Adults and children: executive summary. Clin Infect Dis 2011;52:285–292. - PubMed
-
- Chen SY, Hsueh PR, Chiang WC, et al. Predicting high vancomycin minimum inhibitory concentration isolate infection among patients with community-onset methicillin-resistant Staphylococcus aureus bacteraemia. J Infect 2014;69:259–265. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources